Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Artificial intelligence for cancer-associated thrombosis risk assessment.

Ferroni P, Roselli M, Zanzotto FM, Guadagni F.

Lancet Haematol. 2018 Sep;5(9):e391. doi: 10.1016/S2352-3026(18)30111-X. No abstract available.

PMID:
30172343
2.

Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer.

Ferroni P, Roselli M, Buonomo OC, Spila A, Portarena I, Laudisi A, Valente MG, Pirillo SP, Fortunato L, Costarelli L, Cavaliere F, Guadagni F.

Anticancer Res. 2018 Aug;38(8):4705-4712. doi: 10.21873/anticanres.12777.

PMID:
30061239
3.

Circulating Biomarkers In Migraine. New Opportunities For Precision Medicine.

Ferroni P, Barbanti P, Spila A, Fratangeli F, Aurilia C, Fofi L, Egeo G, Guadagni F.

Curr Med Chem. 2018 Jun 22. doi: 10.2174/0929867325666180622122938. [Epub ahead of print]

PMID:
29932027
4.

Genetic bases of the nutritional approach to migraine.

De Marchis ML, Guadagni F, Silvestris E, Lovero D, Della-Morte D, Ferroni P, Barbanti P, Palmirotta R.

Crit Rev Food Sci Nutr. 2018 Mar 8:1-13. doi: 10.1080/10408398.2018.1450215. [Epub ahead of print]

PMID:
29517920
5.

Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology.

Ferroni P, Zanzotto FM, Scarpato N, Riondino S, Guadagni F, Roselli M.

Dis Markers. 2017;2017:8781379. doi: 10.1155/2017/8781379. Epub 2017 Sep 17.

6.

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations.

Barbanti P, Ferroni P.

J Pain Res. 2017 Sep 29;10:2319-2329. doi: 10.2147/JPR.S113614. eCollection 2017. Review.

7.

Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions.

Ferroni P, Barbanti P, Della-Morte D, Palmirotta R, Jirillo E, Guadagni F.

Antioxid Redox Signal. 2018 Apr 20;28(12):1144-1183. doi: 10.1089/ars.2017.7260. Epub 2017 Nov 21.

PMID:
28990418
8.

Microbubble technique in failed deep anterior lamellar keratoplasty: 2-year outcomes.

Lippera S, Pallotta G, Ferroni P, Lippera M, Spadea L, Cagini C.

Eur J Ophthalmol. 2018 Mar;28(2):243-245. doi: 10.5301/ejo.5001038.

PMID:
28967073
9.

Editorial: Non-Communicable Diseases: Gender Differences in Therapy.

Ferroni P.

Curr Med Chem. 2017;24(24):2559-2560. doi: 10.2174/092986732424170911112453. No abstract available.

PMID:
28911300
10.

Procoagulant imbalance in premenopausal women with chronic migraine.

Ferroni P, Barbanti P, Aurilia C, Egeo G, Fofi L, La Farina F, Valente MG, De Marchis ML, Spila A, Palmirotta R, Della-Morte D, Guadagni F.

Neurology. 2017 Oct 3;89(14):1525-1527. doi: 10.1212/WNL.0000000000004435. Epub 2017 Aug 25. No abstract available.

PMID:
28842452
11.

Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer.

Guadagni F, Riondino S, Formica V, Del Monte G, Morelli AM, Lucchetti J, Spila A, D'Alessandro R, Della-Morte D, Ferroni P, Roselli M.

World J Gastroenterol. 2017 Jul 28;23(28):5187-5195. doi: 10.3748/wjg.v23.i28.5187.

12.

The role of anti-CGRP antibodies in the pathophysiology of primary headaches.

Barbanti P, Aurilia C, Fofi L, Egeo G, Ferroni P.

Neurol Sci. 2017 May;38(Suppl 1):31-35. doi: 10.1007/s10072-017-2907-8. Review.

PMID:
28527063
13.

Biological and predictive role of ERCC1 polymorphisms in cancer.

Formica V, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau HT, Guadagni F, Orlandi A, Roselli M.

Crit Rev Oncol Hematol. 2017 Mar;111:133-143. doi: 10.1016/j.critrevonc.2017.01.016. Epub 2017 Jan 28. Review.

PMID:
28259288
14.

Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.

Riondino S, Del Monte G, Fratangeli F, Guadagni F, Roselli M, Ferroni P.

Cardiovasc Hematol Agents Med Chem. 2017;15(1):3-16. doi: 10.2174/1871525715666170127101605. Review.

PMID:
28137223
15.

Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer.

Vergati M, Krasniqi E, Monte GD, Riondino S, Vallone D, Guadagni F, Ferroni P, Roselli M.

Curr Med Chem. 2017;24(12):1170-1185. doi: 10.2174/0929867324666170116122915. Review.

PMID:
28093985
16.

Prognostic value of glycated hemoglobin in colorectal cancer.

Ferroni P, Formica V, Della-Morte D, Lucchetti J, Spila A, D'Alessandro R, Riondino S, Guadagni F, Roselli M.

World J Gastroenterol. 2016 Dec 7;22(45):9984-9993. doi: 10.3748/wjg.v22.i45.9984.

17.

Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.

Formica V, Morelli C, Ferroni P, Nardecchia A, Tesauro M, Pellicori S, Cereda V, Russo A, Riondino S, Guadagni F, Roselli M.

Cancer Biomark. 2016 Sep 26;17(3):335-345.

PMID:
27434293
18.

Oxidant stress as a major determinant of platelet activation in invasive breast cancer.

Ferroni P, Santilli F, Cavaliere F, Simeone P, Costarelli L, Liani R, Tripaldi R, Riondino S, Roselli M, Davi G, Guadagni F.

Int J Cancer. 2017 Feb 1;140(3):696-704. doi: 10.1002/ijc.30488. Epub 2016 Nov 7.

19.

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.

Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R.

J Thorac Oncol. 2016 Nov;11(11):1993-2005. doi: 10.1016/j.jtho.2016.07.033. Epub 2016 Aug 17.

20.

Gender Differences in Cancer-associated Venous Thromboembolism.

Riondino S, Guadagni F, Formica V, Ferroni P, Roselli M.

Curr Med Chem. 2017;24(24):2589-2601. doi: 10.2174/0929867323666161018144505. Review.

PMID:
27758714
21.

The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy.

Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J.

Oncoimmunology. 2016 May 19;5(7):e1188243. doi: 10.1080/2162402X.2016.1188243. eCollection 2016 Jul.

22.

Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.

Hamilton DH, Roselli M, Ferroni P, Costarelli L, Cavaliere F, Taffuri M, Palena C, Guadagni F.

Endocr Relat Cancer. 2016 Oct;23(10):783-796. doi: 10.1530/ERC-16-0037.

23.

Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients.

Ferroni P, Zanzotto FM, Scarpato N, Riondino S, Nanni U, Roselli M, Guadagni F.

Med Decis Making. 2017 Feb;37(2):234-242. doi: 10.1177/0272989X16662654. Epub 2016 Aug 19.

PMID:
27491558
24.

Functional impairment of activated protein C in breast cancer - relationship to survival outcomes.

Roselli M, Ferroni P, Riondino S, Mariotti S, Portarena I, Alessandroni J, Ialongo C, Massoud R, Costarelli L, Cavaliere F, Bernardini S, Guadagni F.

Am J Cancer Res. 2016 Jun 1;6(6):1450-7. eCollection 2016.

25.

Low-grade endotoxemia and clotting activation in the early phase of pneumonia.

Cangemi R, Della Valle P, Calvieri C, Taliani G, Ferroni P, Falcone M, Carnevale R, Bartimoccia S, D'Angelo A, Violi F; SIXTUS Study Group.

Respirology. 2016 Nov;21(8):1465-1471. doi: 10.1111/resp.12854. Epub 2016 Jul 12.

PMID:
27403788
26.

Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease.

Vazzana N, Santilli F, Lattanzio S, Liani M, Giacci L, Del Rosso G, Salvati F, Boccatonda A, Ferroni P, Davì G.

Eur J Intern Med. 2016 Sep;33:74-80. doi: 10.1016/j.ejim.2016.06.016. Epub 2016 Jul 4.

PMID:
27389698
27.

Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression.

Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, D'Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M.

Oncologist. 2016 Sep;21(9):1041-9. doi: 10.1634/theoncologist.2015-0462. Epub 2016 Jul 7.

28.

Insulin resistance as a predictor of venous thromboembolism in breast cancer.

Ferroni P, Roselli M, Riondino S, Cavaliere F, Guadagni F.

Endocr Relat Cancer. 2016 Jun;23(6):L25-8. doi: 10.1530/ERC-16-0187. Epub 2016 May 16. No abstract available.

PMID:
27185869
29.

VEGF and VTE Risk in Cancer Patients--Letter.

Ferroni P, Riondino S, Guadagni F, Roselli M.

Clin Cancer Res. 2016 Mar 1;22(5):1295. doi: 10.1158/1078-0432.CCR-15-2699. No abstract available.

30.

Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management.

La Farina F, Raparelli V, Napoleone L, Guadagni F, Basili S, Ferroni P.

Cardiovasc Hematol Disord Drug Targets. 2016;15(3):187-203. Review.

PMID:
26721521
31.

Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle.

Riondino S, Ferroni P, Spila A, Alessandroni J, D'Alessandro R, Formica V, Della-Morte D, Palmirotta R, Nanni U, Roselli M, Guadagni F.

Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):291-9. Review.

PMID:
26543078
32.

VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.

Ferroni P, Palmirotta R, Riondino S, De Marchis ML, Nardecchia A, Formica V, Guadagni F, Roselli M.

Thromb Haemost. 2016 Jan;115(1):143-51. doi: 10.1160/TH15-03-0259. Epub 2015 Sep 3.

PMID:
26336029
33.

Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress.

Ferroni P, Riondino S, Buonomo O, Palmirotta R, Guadagni F, Roselli M.

Oxid Med Cell Longev. 2015;2015:183928. doi: 10.1155/2015/183928. Epub 2015 Jun 11. Review.

34.

Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study.

De Marchis ML, Barbanti P, Palmirotta R, Egeo G, Aurilia C, Fofi L, Piroso S, Ialongo C, Della-Morte D, D'Andrea G, Ferroni P, Guadagni F.

J Headache Pain. 2015;16:520. doi: 10.1186/s10194-015-0520-x. Epub 2015 Apr 30.

35.

Platelet Function: the Janus face of haemostasis in cirrhosis.

Raparelli V, Basili S, Ferroni P.

Thromb Res. 2015 Jun;135(6):1224-5. doi: 10.1016/j.thromres.2015.04.009. Epub 2015 Apr 14. No abstract available.

PMID:
25910518
36.

Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women.

Basili S, Raparelli V, Proietti M, Napoleone L, Ferroni P, Franconi F.

Curr Vasc Pharmacol. 2015;13(6):738-48. Review.

PMID:
25686858
37.

Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.

Della-Morte D, Riondino S, Ferroni P, Palmirotta R, Pastore D, Lauro D, Guadagni F, Roselli M.

Pharmacogenomics. 2015 Jan;16(1):61-78. doi: 10.2217/pgs.14.136. Review.

PMID:
25560471
38.

Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

Della-Morte D, Palmirotta R, Rehni AK, Pastore D, Capuani B, Pacifici F, De Marchis ML, Dave KR, Bellia A, Fogliame G, Ferroni P, Donadel G, Cacciatore F, Abete P, Dong C, Pileggi A, Roselli M, Ricordi C, Sbraccia P, Guadagni F, Rundek T, Lauro D.

Pharmacogenomics. 2014 Dec;15(16):2063-82. doi: 10.2217/pgs.14.162. Review.

39.

Progesterone receptor gene (PROGINS) polymorphism correlates with late onset of migraine.

Palmirotta R, Barbanti P, Ialongo C, De Marchis ML, Alessandroni J, Egeo G, Aurilia C, Fofi L, Valente MG, Ferroni P, Della-Morte D, Guadagni F.

DNA Cell Biol. 2015 Mar;34(3):208-12. doi: 10.1089/dna.2014.2534. Epub 2014 Dec 10.

40.

Is SOD2 Ala16Val polymorphism associated with migraine with aura phenotype?

Palmirotta R, Barbanti P, De Marchis ML, Egeo G, Aurilia C, Fofi L, Ialongo C, Valente MG, Ferroni P, Della-Morte D, Guadagni F.

Antioxid Redox Signal. 2015 Jan 20;22(3):275-9. doi: 10.1089/ars.2014.6069. Epub 2014 Nov 11.

41.

Predictive value of HDL cholesterol for cancer-associated venous thromboembolism during chemotherapy.

Ferroni P, Roselli M, Riondino S, Guadagni F.

J Thromb Haemost. 2014 Dec;12(12):2049-53. doi: 10.1111/jth.12737. Epub 2014 Oct 17.

42.

Diagnostic procedures for paraffin-embedded tissues analysis in pharmacogenomic studies.

Palmirotta R, De Marchis ML, Ludovici G, Ferroni P, Abete P, Guadagni F, Della-Morte D.

Methods Mol Biol. 2014;1175:45-65. doi: 10.1007/978-1-4939-0956-8_4.

PMID:
25150866
43.

Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.

Formica V, Luccchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, Tesauro M, Cereda V, Guadagni F, Roselli M.

Med Oncol. 2014 Sep;31(9):166. doi: 10.1007/s12032-014-0166-6. Epub 2014 Aug 23.

PMID:
25148896
44.

Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy.

Ferroni P, Guadagni F, Riondino S, Portarena I, Mariotti S, La Farina F, Davì G, Roselli M.

Haematologica. 2014 Oct;99(10):1638-44. doi: 10.3324/haematol.2014.109470. Epub 2014 Aug 1.

45.

Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.

Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L, La Farina F, Valente MG, Vergati M, Guadagni F, Roselli M.

Int J Cancer. 2015 Mar 1;136(5):1234-40. doi: 10.1002/ijc.29076. Epub 2014 Jul 23.

46.

Obesity and colorectal cancer: role of adipokines in tumor initiation and progression.

Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F.

World J Gastroenterol. 2014 May 14;20(18):5177-90. doi: 10.3748/wjg.v20.i18.5177. Review.

47.

Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.

48.

Clinical models and biochemical predictors of VTE in lung cancer.

Roselli M, Riondino S, Mariotti S, La Farina F, Ferroni P, Guadagni F.

Cancer Metastasis Rev. 2014 Sep;33(2-3):771-89. doi: 10.1007/s10555-014-9500-x. Review.

PMID:
24748012
49.

Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy.

Ferroni P, Guadagni F, Laudisi A, Vergati M, Riondino S, Russo A, Davì G, Roselli M.

Oncologist. 2014 May;19(5):562-7. doi: 10.1634/theoncologist.2013-0339. Epub 2014 Apr 7.

50.

Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome.

Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F.

Anticancer Res. 2014 Mar;34(3):1153-61.

PMID:
24596353

Supplemental Content

Loading ...
Support Center